Global fund changes tack on malaria therapy

Article Abstract:

The Geneva-based Global Fund to Fight AIDS, tuberculosis and malaria agreed too instruct African countries to retrospectively modify all malaria grants awarded to specify only the newer drug. Donors such as the US and Britain has discouraged African countries from adopting artemisinin on the grounds that it cost much, that data on its effect in children are insufficient and that it was not needed in regions where other anti-malaria drugs still worked.

Financial management, Africa, Care and treatment, Finance, AIDS (Disease), Malaria, Company financing

---

Raiding the medicine cabinet

Article Abstract:

This article discusses the paucity or unavailability of drugs to fight diseases in the developing countries and the reasons for it. The work of Medecins Sans Frontieres or Doctors Without Borders is presented. This organization has been addressing the neglected diseases of the developing world and is striving to bing hope to the world's disaster zones.

World, Developing Countries, Health aspects, International aspects, Diseases, Doctors Without Borders

---

The farmyard drug store

Article Abstract:

The reality of the pharmaceuticals made from genetically modified animals is investigated. The biopharmaceutical companies like GTC Biotherapeutics and Pharming Group are continuing their slow progress into the animal market as many failures have created a negative image of the transgenic animal market.

United States, Product development, Forecasts, trends, outlooks, Pharmaceutical industry, Forecasts and trends, Market trend/market analysis, Genetically modified animals

Similar abstracts:

• Abstracts: Without a way to measure their success, Japanese projects are very hard to stop. Japanese physicists say SSC will hurt domestic research
• Abstracts: Filling in the background. The red planet's big picture. The impact of deep impact
• Abstracts: Hydrous olivine unable to account for conductivity anomaly at the top of the asthenosphere
• Abstracts: Dying cells dragged screaming under the microscope. The first wave
• Abstracts: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. CYLD is a deubiquitinating enzyme that negatively regulates NF-(kappa)B activation by TNFR family members

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.